Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Long-Term Investments (2020 - 2021)

Insight Molecular Diagnostics (IMDX) has disclosed Long-Term Investments for 2 consecutive years, with $2.0 million as the latest value for Q1 2021.

  • Quarterly Long-Term Investments fell 6.18% to $2.0 million in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Mar 2021, down 6.18% year-over-year, with the annual reading at $13.4 million for FY2020, N/A changed from the prior year.
  • Long-Term Investments hit $2.0 million in Q1 2021 for Insight Molecular Diagnostics, down from $13.4 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $14.3 million in Q2 2020 to a low of $2.0 million in Q1 2021.